Declined international medical insurance claims, and how to appeal them

When a claim is refused, something specific has happened: an assessor has matched the facts of your treatment against a provision in the wording and concluded that the provision applies. That is a narrower event than it feels like, and the narrowness is what makes it possible to challenge.

The useful question is therefore never why they will not pay. It is which clause, and on what evidence. Almost every successful appeal consists of new material addressed at one identified provision; almost every unsuccessful one is a general account of how unfair the outcome is, sent to a claims team with no authority to depart from the wording.

The grounds fall into three groups: what you disclosed, where your cover's boundaries sit, and whether the treatment itself qualifies. The third is the least understood and increasingly the most important.

The second group is where most declines sit, and none implies you did anything wrong.

Pre-existing and linked conditions under a moratorium. A moratorium excludes conditions from before you joined until you have completed a defined period of membership and a defined trouble-free period. The trap is linkage: insurers publish tables connecting conditions to others they will also decline. A diabetes diagnosis can carry ischaemic heart disease with it; treated hypertension can carry cataract, diabetic retinopathy, arterial disease and stroke. The claim being declined may be for a condition you have never been treated for, on the basis of one you were — see how the moratorium clock actually works and linked exclusions.

Benefit exhausted or an inner limit reached. The annual maximum is rarely the constraint. Inner limits are — a per-year cap on a specific benefit, a lifetime cap on mental health treatment, a per-transplant limit, a night-count on accommodation. A claim can be refused while millions remain on the headline limit, as explained in annual benefit limits and inner limits.

Treatment outside the area of cover. Zone structures are more granular than most members realise: some zones exclude a territory entirely, others cover it only on a restricted emergency basis with a monetary cap and a trip-length limit. Treatment sought during a trip that ran past the permitted duration is outside cover even though the territory appears on the certificate. See area of cover explained.

An unexpired waiting period. Maternity, well-being benefits, preventive cancer treatment, HIV treatment and dental cover commonly carry their own clocks, running from your date of entry rather than from renewal.

No pre-authorisation. Usually a reduction rather than a refusal — one wording reimburses 80% of eligible costs, another may cover 75% where the treatment is later proven medically necessary. But some categories, notably treatment in the United States under a plan with restricted US cover, are not paid at all without prior authorisation. See how an IPMI claim works.

A reasonable and customary shortfall. Where a provider charges materially above the local going rate, the insurer pays the customary amount and the balance is yours. That is a partial decline, and it is often mistaken for an administrative error.

Ask for the decline in writing, with the clause relied on and the evidence used — not a benefit code, and not a verbal summary. You cannot appeal what you cannot see, and a decision that cannot be tied to a provision is sometimes one that has not been properly made, so the request itself occasionally resolves the matter.

Ask at the same time what further evidence would cause the decision to be reconsidered. It saves commissioning the wrong report. Wordings generally place the cost of additional medical information on the member — including any independent medical examination the insurer requires — and provide that refusing to supply reasonably requested information means the claim cannot be assessed at all.

An internal appeal is then a request to reconsider on new material aimed at the identified ground.

If the ground is that a condition is pre-existing or linked to one, the evidence needed is clinical: a consultant's letter addressing date of onset, the absence of prior symptoms, investigation or medication, and, where relevant, why the current condition is not pathologically linked to the earlier one. If the ground is medical necessity, the letter must explain why this treatment, at this time, in this setting, was clinically indicated, and what the alternatives were. If the ground is that the treatment is unproven, the response has to engage with the test on its own terms — the marketing authorisation and the indication, the trial evidence, or recognition by an authoritative medical body in the country of treatment.

If the ground is a limit, geography or a waiting period, new clinical evidence will not help. Those are arithmetic and calendar questions, and the appeal is either a factual correction — a date, a zone, a benefit misallocated to the wrong heading — or it has no prospect. Recognising which kind of ground you are facing saves months.

Here is the part that catches people out, and it is structural rather than procedural. The external route is determined by who carries the risk and where that entity is regulated, not by the brand on your card.

International medical cover is routinely arranged by one company, administered and claims-handled by another, and underwritten by a third in a different country. Two current client wordings show how far apart the answers can be.

Under the William Russell arrangement, the product is arranged by a Belgian-registered entity whose UK branch is FCA-authorised, William Russell acts as mandated underwriter for policy administration, claims handling and complaint handling, and the risk sits with a French insurer regulated by the ACPR. The wording accordingly directs UK-based customers to the UK Financial Ombudsman Service and non-UK customers to La Médiation de l'Assurance in Paris.

Under the NIMBL arrangement, an FCA-authorised UK company acts as managing general agent on behalf of a French mutual insurer, with a Portuguese affiliate as insurer for some members. Complaints are handled primarily under FCA rules, with the wording noting that for certain types the insurer is ultimately responsible and telling the member which applies. Dissatisfied complainants may be entitled to refer the matter to the UK Financial Ombudsman Service — the conditional phrasing reflects that eligibility depends on complainant status, not merely on holding the policy. Separate mediation routes exist for group schemes and for members insured through the Portuguese entity.

Two points generalise from that, and no more. Access to a national ombudsman depends on where the regulated entity sits, where you are resident, and whether you count as an eligible complainant under that scheme's rules — there is no single global ombudsman for international medical insurance, and any source implying otherwise is describing one country's arrangements. And identifying the risk carrier is the prerequisite for everything else, which is the subject of who carries the risk and a check worth running at purchase, alongside insurer solvency and due diligence.

Where no ombudsman has jurisdiction, the residual routes are the insurer's home regulator and the courts — which is what wordings mean when they note that these rights are without prejudice to legal action.